Adjuvant induced arthritis (AA) in Buffalo rats is a chronic progressive disease that responds very well to treatment with myeloablation and rescue with autologous BM. These previous results were obtained by conditioning with a lethal single dose of TBI. In the present study various other conditioning regimens were compared with single dose TBI. Fractionated TBI using adjusted total dose was equally effective. CY and BU when used as single agents at the highest tolerated dose were less effective. Combinations of CY (2 ؋ 60 mg/kg) with lower dose (4 Gy) TBI and of BU with CY were as beneficial as high-dose TBI. These results indicate that a very intense reduction of T lymphocytes, in the order of 3-4 log, is required for obtaining the highest rate of long-lasting complete remissions. A similar conclusion was reached from our studies of various conditioning regimens in rats suffering from experimental allergic encephalitis (EAE). If extrapolated to the clinic, such a degree of T lymphocyte eradication poses upper limits to the number of T lymphocytes that can be safely reintroduced with the autograft. The exact limits cannot be derived from these experiments because the addition of autologous T lymphocytes to the graft yielded different results in the two models of autoimmune disease (AID). Bone Marrow Transplantation (2000) 25, 357-364. Keywords: autologous BMT; conditioning; autoimmune disease; rats
because of its associated risk of mortality, allogeneic BMT has not so far been applied to the treatment of refractory AID.
The observation that autologous BMT can be as effective as allogeneic marrow in inducing complete remissions in rats with AA 7 or EAE 8 has paved the way for clinical studies of this new approach because autologous BMT carries less risk than allogeneic BMT.
In our previous research successful treatment of AA with BMT was achieved using high-dose total body irradiation (TBI) as the conditioning agent. 1, 7 Partial body irradiation did not result in lasting complete remissions. The design of clinical protocols revealed a need for information on the efficacy of conditioning with high-dose chemotherapy or with cytotoxic drugs in combination with TBI. In the EAE model conditioning with a combination of CY and a sublethal dose of TBI (7 Gy) was shown to be as effective as a supralethal dose of 10 Gy TBI, while the combination of BU and CY was nearly as effective. 8 Here, we present data on the treatment with similar conditioning regimens of rats suffering from chronic progressive AA. We also investigated the efficacy of fractionated TBI as compared with single-dose TBI because many BMT teams prefer to deliver TBI in fractions.
Adjuvant-induced arthritis is a well established and widely employed experimental model for systemic rheumatoid arthritis. In Buffalo rats it develops as a severe progressive chronic polyarthritis. Between 3 and 4 weeks after immunization an acute inflammation of the synovia begins, leading to pannus formation, subchondrial erosion and destruction of cartilage. After about 2 months the inflammatory reaction gradually diminishes and is replaced by abnormal bone and scar tissue formation. However, active foci of lymphocytes and plasma cells continue to be present in the lesions of some animals up to 12 months after induction. Our previous studies showed that BMT only abrogates the inflammatory processes; the osseous malformations, once established, are not influenced by this treatment.
To avoid surgical intervention for the purpose of harvesting BM from very sick animals, we employed instead BM from syngeneic animals that were sacrificed at exactly the same stage and severity of the disease as were the recipients at the time of treatment. This graft was termed pseudo-autologous in previous publications. It is identical to autologous BM in all aspects. In order to avoid confusion in translating our experimental results to clinical protocols we shall in the following use the term autologous for both pseudo-autologous and autologous BM grafts.
In the AA rats treated with autologous BMT, spon-taneous relapses among the responders are extremely rare. In this respect AA differs from the EAE model, where the incidence of spontaneous relapses is about 30%. In EAE, relapses can also be induced in a large proportion of cured animals by reimmunization, while this is a rare event in AA. Evidence has been presented in EAE that both types of relapses may be caused by residual T lymphocytes of the host that survive the conditioning, as well as by T lymphocytes that are reintroduced with the graft. Although the mechanisms underlying relapses in human AID are unknown, it seemed useful to collect more information on the frequency of induced relapses following treatment of AA with autologous BMT. Finally, we investigated whether the incidence of induced relapses is increased by the addition of autologous lymphocytes to the BM graft, as was the case in EAE.
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Materials and methods
Male and female rats of the inbred Buffalo (BUF/SimRij) strain (RTI b ) aged 12-16 weeks were bred under specific pathogen-free conditions in the animal facilities of TNO (Rijswijk, The Netherlands) or purchased from Harland, Zeist, The Netherlands. They were fed a commercial pelleted diet and received acidified water ad libitum.
To induce arthritis, between 90 and 100 rats were injected intradermally at the root of the tail with a suspension of 1 mg of M. tuberculosis (H37Ra, Difco, Detroit, MI, USA) in IFA (Difco) in a volume of 0.1 ml according to Pearson and Wood. 9 This resulted in severe arthritis in 70-90% of the animals within 4 weeks. The thickness of the ankle and wrist joints were measured with a caliper before the immunization and weekly thereafter. The severity of arthritis was expressed as the arthritic score for each individual animal, being the sum of the measures of the four paws substracted by the measures recorded before the immunization. Mean arthritic scores were derived by averaging the individual scores of rats within an experimental group. There is a certain variation in the responses between individual rats, as well as between similarly treated or untreated control groups in different experiments. Before starting treatment, all arthritis-positive animals were allocated to groups of 10, taking care that the distribution of arthritic scores was similar in all groups. Between different experiments the mean arthritic scores varied from 8 to 12. Each experiment consisted of six to nine groups of 10 rats each, including an untreated control group (to allow for inter-experiment variations) as well as a donor group. The latter animals were sacrificed on the day of transplantation. After treatment, the arthritic scores were recorded weekly for the duration of the experiment. At 15 weeks after immunization, that is at 11 weeks after BMT, the animals were reimmunized and observed for another 10-12 weeks until the experiment was terminated.
For TBI, rats were placed in a circular perspex box and exposed to 300 kV X-rays at a dose rate of 0.34 Gy/min from a Philips-Muller 300 machine (Hamburg, Germany). CY (Endoxan, a generous gift from Asta, Diemen, The Netherlands) was diluted to a concentration of 45 mg/ml in PBS before i.p. administration. Mesna (Dagra Pharma, Diemen, The Netherlands) was injected i.p. at a dose of 80 mg/kg just before and 7 h after the administration of CY in order to prevent hemorrhagic cystitis. BU (Wellcome, London, UK) was administered by gastric tube as a suspension in PBS at a concentration of 6 mg/ml. BM cells were harvested from all rats of the donor group. After sacrifice, the long bones were dissected and the marrow was flushed out with phosphate-buffered saline (PBS), pooled, filtered through nylon gauze and counted in a hemocytometer using Türks solution for total nucleated cells and 0.2% eosin for the determination of dead cells. Numbers of cells grafted refer to viable cells. All animals received a standard BM graft of 2 ϫ 10 7 cells. The proportion of T lymphocytes in rat BM is about 3%, that is 10 times lower than in human BM. Suspensions of spleen and mesenterial lymph nodes were prepared in a similar way. Blood was collected in heparin solution by exsanguination, diluted with an equal volume of PBS and centrifuged at 600 g for 20 min over Ficoll to separate the nucleated cells. Cells were injected into the tail vein under slight ether anaesthesia in a volume of 1 ml within 24 h after irradiation and, in the case of conditioning with cytostatics, 48 h after the last injection.
Results

General observations
The responses to treatment were characteristically a gradual decrease of swelling and redness of the joints in the course of from 4 to 10 weeks. Rats that reached a stable arthritic score of 3, 2 or 1 were listed as complete responders. Such minimal residual thickening in the absence of soft tissue swelling and redness of the skin may occur as a result of abnormal bone formation which had taken place prior to the BM. Rats that reached a score of 0 were listed as completely cured. A decrease of the arthritic score by 3 points or more which stabilized at any value over 3 was listed as a partial response. Non-responders did not show a decrease of the arthritic score by more than 2 points.
In the large majority of the untreated controls the disease progressed or stabilized at a high arthritic score. A few animals spontanously went into remission but this never resulted in complete cure; 8% reached a complete response and 4% a partial response (Table 1 ). In the other 88% the disease remained stable or progressed. Reimmunization did Table 1 Course of arthritis without treatment in different experiments not significantly affect the arthritic score in the untreated controls.
In every experiment one group was treated with 9 Gy single-dose TBI prior to BMT, which was the highest dose tolerated by these very sick animals. Only two out of 50 of such positive control rats died during the immediate posttransplantation period. The majority, ie 71%, reached a complete response with 19% completely cured, while 29% improved to reach a partial response (Table 2 ). There was one spontanous relapse among the complete responders. Two of the partial responders and one of the complete responders developed a distinct exacerbation after the reimmunization.
Total body irradiation: single dose vs fractionated irradiation
Fractions of 2.5 Gy were administered six times over a period of 3 days to a total dose of 15 Gy. Fractions of 3 Gy were given four times over 48 h to a total dose of 12 Gy. A third group received two fractions of 5 Gy on each of 2 consecutive days. These fractionation regimens were compared with 9 Gy delivered as a single dose. The fractionated total doses were calculated to be biologically equivalent to 9 Gy single exposure, using LD50 30 day values of mice exposed to fractionated and single-dose TBI. 10, 11 The mortality in these experiments was due to myeloablation.
As shown in Figure 1 , all irradiation schedules were equally effective in inducing remissions. Spontanous relapses did not occur. After reimmunization at week 15, two mild exacerbations were seen in the two times 5 Gy group and one severe relapse occurred in the four times 3 Gy group (Figure 2 ). The distribution of complete and partial responders is presented in Table 3 . Non-responders were not seen in any of the treated groups.
Cyclophosphamide as a single agent or combined with TBI
The highest tolerated doses for single (120 mg/kg) and two fraction administration (80 mg/kg ϫ 2) with BM support were determined in prior separate toxicity studies using normal animals. In arthritic rats, this conditioning resulted in partial responses of the majority of the animals ( Figure  3 ). In the 120 mg/kg group (Table 4) there were only two Abbreviations as in Table 1 . 
Abbreviations as in Table 1 . complete responders. Three of the rats with a partial remission developed an exacerbation before reimmunization and four rats did so after reimmunization (Figure 4 ). The responses of the two times 80 mg/kg and of the two times 60 mg/kg groups showed essentially similar patterns as the single dose 120 mg/kg group. Conditioning with a combination of two times 60 mg/kg of CY and 4 or 7 Gy of TBI on the day of the second CY administration induced complete responses in all except one of the animals, without spontanous relapses.
The difference in complete response rate between the Arthritic score
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Figure 4
Changes of the arthritic score of individual rats from the group that was conditioned with a single dose of 120 mg/kg CY.
groups treated with CY alone and those conditioned with TBI or the combined regimens was statistically significant (chi square test: P Ͻ 0.001). Upon reimmunization, the one rat in the CY plus 4 Gy group with a partial response developed a relapse. Exacerbations did not occur in the CY plus 7 Gy group. Interestingly, in the positive control group of this experiment which was conditioned with 9 Gy TBI ( Figure 5 ) reimmunization caused two relapses, one in a partial responder and one among the complete responders. The other partial responder exacerbated before the reimmunization and represents the only spontanous relapse ever observed after con- ditioning with 9 Gy TBI. The pattern of this particular group was rather exceptional since in all the other positive control groups together only one rat relapsed after reimmunization (Table 2) .
Busulfan as a single agent and combined with cyclophosphamide
Twenty mg/kg is the highest tolerated dose of BU with BM support. It induces partial remissions in 70% of the cases, but combined with 120 mg/kg of CY divided over two fractions the results are nearly as good as with 9 Gy TBI ( Figure 6 and Table 5 ). The difference in complete response incidence between the groups receiving single agent treatment and those conditioned with the BU/CY combinations or TBI was statistically significant (chi square test: P Ͻ 0.001).
In this experiment a few exacerbations were seen after reimmunization. They occurred in the 10 mg BU only, the 20 mg BU only and in the CY only groups, again suggestive of inadequate conditioning as a cause of induced exacerbations.
Addition of autologous lymphatic cells to the graft
As is apparent from Figure 7 , none of the additions seemed to influence the favorable outcome of treatment with 9 Gy TBI and rescue with autologous BM cells. A more detailed analysis is presented in Table 6 . The two groups given Table 1 .
spleen cells with three partial responders each appear to respond slightly less favorably than the groups given blood cells or lymph node cells with only one partial responder in each. However, comparison with the BM only group included in this experiment or with all the other BM only groups listed in Table 2 leads to the conclusion that there is no effect of the added autologous spleen cells.
Bone Marrow Transplantation Table 1 .
Discussion
Since AA, like clinical rheumatoid disease, is T cell dominated, the conditioning has to be targeted at the T lymphocytes. The agents employed in the present study are also strongly myeloablative. More specific lympho-ablative agents could not be tested in the rat model. Available antirat lymphocytic antibodies were not sufficiently lymphoablative or cross-reacted with hemopoietic stem cells. The pharmacokinetics of drugs such as 2-chlorodeoxyadenosine in rats differ greatly from that in man. Cyclosporin A suppresses AA, but as in patients, the disease relapses after the treatment is discontinued.
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Of the single agents tested at the highest tolerated dose, TBI is clearly the most effective. Its dose distribution over the various tissues is known to be very homogenous while that of CY and BU is less well documented. The agents can best be compared by using TBI as the reference, since at least some estimates are available regarding the radiosensitivity of T lymphocytes. The radiosensitivity of a cell population is characterized by a dose-survival curve, which is defined by the slope of the straight part and by the extrapolation number for the shoulder. The slope is defined by the radiation dose (D 0 ) which corresponds with a surviving fraction of 0.37 (e Ϫ1 ). D 0 values for T lymphocytes vary between 0.8 Gy and 1.55 Gy depending on the phenotypic subpopulations and the end points. [12] [13] [14] [15] [16] [17] [18] The extrapolation numbers are usually small -in the order of 1.5. It is unknown at present which subpopulations are pivotal for the progression of AID.
The best results with a single agent were seen in AA with a TBI of 9 Gy and in EAE with a TBI of 10 Gy, which according to the above radiosensitivity values would induce roughly a 3-4 log kill of T lymphocytes. Fractionated TBI is equally effective, provided the total dose is adjusted ( Table 3) .
Assuming that a similar immuno-ablation is required for effective treatment of patients and setting the total lymphatic mass of an adult at 10 12 lymphocytes (of which 30% are T cells), only between 3 ϫ 10 7 and 3 ϫ 10 8 T lymphocytes would survive the conditioning. This outcome underlines the necessity for T cell depletion of the autologous graft, which in the case of mobilized peripheral blood cells of patients may contain as many as 2 ϫ 10 10 T lymphocytes. It seems irrational to reintroduce substantially more T lymphocytes than those surviving after conditioning. The current recommendation is to graft no more than 10 5 T cells/kg, which is on the safe side in view of the calculations presented here.
In that context the absence of adverse effects of adding autologous lymphoid cells to the BM graft in AA was quite unexpected. It is in contrast with results in the EAE model where the addition of 7 ϫ 10 7 autologous spleen cells, containing 40-50% T lymphocytes, tripled the spontaneous relapse rate (from 30% with BM alone to 93%). The number of T lymphocytes contained in the BM graft was calculated at 7 ϫ 10 5 cells. If the total lymphatic tissue mass of the rat is estimated at 3 ϫ 10 9 cells with 30% T cells, 10 Gy TBI leaves between 10 5 and 10 6 residual T cells, which is roughly equal to the number present in the BM graft. The spontaneous relapse rate in the EAE rats was similar after autologous BMT or syngeneic BMT from healthy syngeneic donors, suggesting that under these conditions spontaneous relapses were caused by residual T cells rather than by grafted lymphocytes. The discrepancies between the results obtained with the two disease models after addition of autologous lymphocytes may be related to the fact that EAE in the BUF rat is a chronic remitting relapsing disease while AA runs a chronic progressive course. In contrast to EAE, relapses of either kind are very rare following complete remissions in AA, while exacerbations frequently occur during incomplete remission.
It is unlikely that the number of autologous T lymphocytes administered to the rats with AA has been insufficient. In the case of peripheral blood cells it was 30% of 10 7 = 3 ϫ 10 6 to be compared with 6 ϫ 10 5 in the autologous BM graft. The lymph node cells contained 75% T cells and the spleen cell suspension 45% bringing the number of T cells to 7 ϫ 10 6 and 4.5 ϫ 10 6 or 45 ϫ 10 6 , respectively. On the other hand the assumed radiosensitivity of the T cells responsible for AA also introduces an element of uncertainty. Obviously, the answers to the question of how essential T cell depletion is, can only come from clinical investigations. The first five patients who were treated for a variety of refractory AID including one case of rheumatoid arthritis, received unmodified autologous peripheral blood cells. They all had early recurrences or incomplete remissions. 19 That experience strongly supports the current recommendations for T cell depletion as the best strategy. Considering the variations within each AID and the differences between the various AID it is expected that some recurrences will be seen even after T cell depletion due to inadequate conditioning or to abundance of activated T lymphocytes in the patient. It is equally within the expectations that complete and lasting cures will be observed in some patients who receive unmanipulated bone marrow. Obviously, the optimal treatment for each category of patients will ultimately have to be established in clinical trials.
CY at the highest tolerated dose of 160 mg/kg as a single agent was less effective than 9 Gy TBI (Table 4 ) and the same holds for BU at 20 mg/kg ( Table 5 ). The combination of 120 mg/kg CY with 4 Gy TBI was as effective as 9 Gy TBI. In the EAE model, we found 120 mg/kg CY combined with 7 Gy TBI slightly more effective than 10 Gy TBI. It appears thus that this dose of CY is equivalent to 4-5 Gy TBI or roughly 2 log T cell kill.
However, there are indications for qualitative differences between the lymphocytotoxic effects of the two agents. In treating rats suffering from experimental autoimmune myasthenia gravis (EAMG) Pestronk et al 20 showed CY to be less effective than TBI in eliminating immunological memory. In this case the cells involved were most likely B memory cells, but T memory cells were also reported to be CY-resistant. 21 Several authors have described T memory cells as being radiosensitive, 22, 23 possibly even more so than naive or activated T cells. 24 Clinical experience also indicates that CY as a single agent is inadequate for ablation of memory T cells. In non-sensitized patients with aplastic anemia, the allograft failure rate is low after conditioning with CY alone. However, in patients sensitized by many blood transfusions most allografts are rejected and conditioning with a combination of TBI and CY is required to obtain takes. Obviously, there is not enough information on the numbers and nature of memory lymphocytes in patients with advanced AID and how the sizes of these cell populations vary between patients.
In both our disease models, AA and EAE as well as in EAMG, 16 the combination of CY with moderate-dose TBI was superior to CY alone. That is the rationale for our recommendation to employ the combination protocol for the conditioning of patients with refractory AID of any type. This combination protocol has been used in treating children suffering from severe refractory juvenile chronic arthritis. 25 It was well tolerated and few limited relapses have occurred so far. However, fatalities have been reported due to 'activated macrophage syndrome'. It is not clear whether this complication is related to the conditioning, the use of isolated stem cells which are depleted of T cells, B cells and NK cells, or the underlying disease.
The combination of BU and CY also proved to be quite effective, in fact, only slightly less so than 9 Gy TBI. This finding is in accordance with our previous results in EAE.
In those experiments the dose of BU was slightly higher at 30 mg/kg, a dose which was not tolerated by rats with AA. There were more spontanous relapses (58%) in the BU ϩ CY-treated EAE rats than after conditioning with 10 Gy TBI (31%). BU is widely held to be predominantly myeloablative and to possess only limited if any immunosuppressive activity. Perhaps this presumption needs revision.
